Assetmark, Inc Hutchmed (China) LTD Transaction History

Assetmark, Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 01, 2022	SELL	$8.63 - $15.52 $1,104 - $1,986	-128 Reduced 63.05%	75 $1,000
Q2 2022 Aug 03, 2022	SELL	$8.59 - $20.77 $16,475 - $39,836	-1,918 Reduced 90.43%	203 $3,000
Q1 2022 May 13, 2022	BUY	$15.52 - $35.65 $13,005 - $29,874	838 Added 65.32%	2,121 $40,000
Q4 2021 Feb 14, 2022	BUY	$28.89 - $35.33 $13,202 - $16,145	457 Added 55.33%	1,283 $45,000
Q3 2021 Nov 12, 2021	BUY	$35.66 - $42.94 $1,497 - $1,803	42 Added 5.36%	826 $30,000
Q3 2020 Nov 13, 2020	BUY	$25.8 - $34.61 $4,334 - $5,814	168 Added 27.27%	784 $25,000
Q2 2020 Aug 11, 2020	BUY	$17.65 - $28.05 $458 - $729	26 Added 4.41%	616 $17,000
Q1 2020 May 12, 2020	SELL	$15.19 - $29.51 $835 - $1,623	-55 Reduced 8.53%	590 $11,000
Q4 2019 Feb 11, 2020	SELL	$17.17 - $25.95 $583 - $882	-34 Reduced 5.01%	645 $16,000
Q1 2019 May 14, 2019	SELL	$21.27 - $30.58 $42 - $61	-2 Reduced 0.29%	679 $21,000
Q4 2018 Feb 13, 2019	BUY	$23.09 - $37.69 $15,724 - $25,666	681 New	681 $16,000

6.88M

6.2K

1.1K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.47B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

Stay updated on Assetmark, Inc with notifications on news.